drugset / Trial / NCT00339144
Study of Dasatinib (BMS-354825) in Patients With Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this study is to determine the maximum tolerated dose (MTD) or the maximum administered dose (MAD) of Dasatinib (BMS-354825) in patients in Japan.
Timeline
- Start
- 2007-01
- Primary completion
- 2008-09
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dasatinib anhydrous | Small molecule | 100 mg | Oral |
| Subject | dasatinib anhydrous | Small molecule | 150 mg | Oral |
| Subject | dasatinib anhydrous | Small molecule | 200 mg | Oral |